|
Potential drug interactions in heart failure patients involving cardiac glycosides
|
|
| Author:
|
KALOYAN GEORGIEV, BRANIMIR KANAZIREV, MARIETA GEORGIEVA, NADEZHDA HVARCHANOVA
|
| Abstract:
|
The heart failure is a chronic progressive disease in which the heart cannot emit enough blood to respond the
metabolic needs of the body. Cardiac glycosides improve the symptoms of heart failure, but according to the
increased knowledge of the pathogenesis of this disease, their role is limited. Nowa days, they are added to patient’s
treatments who have not responded to standard one. The aim of the present study is to evaluate the
pharmacotherapy of heart failure patients, to select patients taking cardiac glycosides and to screen them for pDDI.
Retrospective analysis of the prescriptions at hospital discharged patients in Cardiology Clinic for two-year period
(January 2014 – December 2015) and selection those treated with cardiac glycosides. Out of 1956 patients, 92 were
treated with cardiac glycosides. The software Lexicomp® detected two pDDI in category D (consider therapy
modification). NonpDDIs belonging to the risk category X(avoid combination) were found. The majority of
interactions were in category C (monitor therapy). The number of the taken drugs of patients receiving cardiac
glycosides and the pDDIs have increased with age (> 60) but this is not statistically significant.Inclusion of cardiac
glycosides in the therapy requires very good knowledge of their pharmacological behavior in order to achieve better
clinical outcome and to avoid undesirable effects and possible drug interactions.
|
| Keyword:
|
drug-drug interactions, cardiac glycosides, digoxin, pharmacokinetics, pharmacodynamics
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.02.062
|
| Download:
|
Request For Article
|
|
|